CG Oncology Inc CGON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 252.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 61
- Website
- https://www.cgoncology.com
Comparables
Valuation
|
Metric
|
CGON
|
CLDX
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.57 | 2.70 | 3.46 |
Price/Sales | 252.33 | 224.17 | 5.03 |
Price/Cash Flow | — | — | — |
Price/Earnings
CGON
CLDX
MGNX
Financial Strength
|
Metric
|
CGON
|
CLDX
|
MGNX
|
|---|---|---|---|
Quick Ratio | 46.66 | 29.06 | 2.53 |
Current Ratio | 47.57 | 29.36 | 2.71 |
Interest Coverage | — | — | −128.87 |
Quick Ratio
CGON
CLDX
MGNX
Profitability
|
Metric
|
CGON
|
CLDX
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −15.24% | −19.66% | −59.21% |
Return on Equity (Normalized) | −26.61% | −20.83% | −120.96% |
Return on Invested Capital (Normalized) | −25.60% | −20.72% | −102.88% |
Return on Assets
CGON
CLDX
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cltvhwmly | Xbrh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfknrxmp | Mzflqt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pdvgmwrd | Svpnfv | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fhxwdjry | Qvmgv | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Wrgsnbsnw | Nkmm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wdcqlbrx | Dbrlz | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ckrcnkhl | Dmcq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Zqsfmyl | Vbwd | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cgcbkrhv | Kbsmt | $13.4 Bil | |||
| Incyte Corp
INCY
| Knzlnhqf | Zkytmjx | $12.7 Bil |
United States